📢 $NTLA News: And so the countdown begins... We are proud to share the @US_FDA has accepted Intellia's Biologics License Application (BLA) with Priority Review for our potential one-time #hereditaryangioedema treatment. The PDUFA target action date is March 10, 2027.
Read the full announcement: ir.intelliatx.com/news-relea…